anti-L1CAM ADC / Elthera - LARVOL DELTA

LegoChem aims to fast-track Elthera’s antibody as 2nd independent ADC (Korea Biomedical Review) - "LegoChem Biosciences said on Monday that it signed a license agreement with Elthera, a Swiss biotechnology company, to develop and commercialize a novel antibody-drug conjugate (ADC) therapy using Elthera’s monoclonal antibody. The licensed asset is a monoclonal antibody with a target expressed in a variety of solid tumors including pancreatic, ovarian, breast, lung, and colorectal cancer. Based on the agreement, LegoChem will be responsible for the future development and commercialization of any products incorporating this antibody, including ADC applications. Elthera will receive an upfront payment, progress-dependent development, regulatory milestone payments, cumulative commercial milestone payments, and royalties on net product sales."

Licensing / partnership • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • Thoracic Cancer